Yttrium 90 ibritumomab tiuxetan (zevalun®): A new bullet in the fight against malignant lymphoma?

Biotechnology Journal

Volumn 2, Issue 11, 2007, Pages 1435-1443

  Chapuy, Bjoern ^a   Høhloch, Karin ^a   Trümper, Lorenz ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Antibody; Chemotherapy; Lymphoma; Radiation; Radioimmunotherapy

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG ACCUMULATION; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG RETENTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPLASIA; FOLLICULAR LYMPHOMA; HEALTH CARE COST; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PAIN; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; LYMPHOMA; MODELS, BIOLOGICAL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

MURINAE;

EID: 36448967878     PISSN: 18606768     EISSN: None     Source Type: Journal    
DOI: 10.1002/biot.200700043     Document Type: Review

References (48)

1. Evans, L. S., Hancock, B. W. Non-Hodgkin lymphoma. Lancet 2003, 362, 139-146.
2. Swerdlow, A. J., Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur. J. Nucl. Med. Mol. Imaging 2003, 30 Suppl 1, S3-12.
3. Gupta, R. K., Lister, T. A., Current management of follicular lymphoma. Curr. Opin. Oncol. 1996, 8, 360-365.
4. Marcus, R., Current treatment options in aggressive lymphoma. Leuk. Lymphoma 2003, 44 Suppl 4, S15-27.
5. Anderson, K. C., Bates, M. P., Slaughenhoupt, B. L., Pinkus, G. S. et al., Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984, 63, 1424-1433.
6. Tedder, T. F., Boyd, A. W., Freedman, A. S., Nadler, L. M. et al., The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J. Immunol. 1985, 135, 973-979.
7. Valentine, M. A., Meier, K. E., Rossie, S., Clark, E. A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J. Biol. Chem. 1989, 264, 11282-11287.
8. Grillo-Lopez, A. J., Dallaire, B. K., McClure, A., Weaver, R. et al., Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Curr. Pharm. Biotechnol. 2001, 2, 301-311.
9. Maloney, D. G., Rituximab for follicular lymphoma. Curr. Hematol. Rep. 2003, 2, 13-22.
10. Plosker, G. L., Figgitt, D. P., Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63, 803-843.
11. Coiffier, B., Haioun, C., Ketterer, N., Engert, A. et al., Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92, 1927-1932.
12. Coiffier, B., Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin. Oncol. 2004, 31 (1 Suppl 2), 7-11.
13. Cerny, T., Borisch, B., Intrana, M., Johnson, P. et al., Mechanism of action of rituximab. Anticancer Drugs 2002, 13 Suppl 2, S3-10.
14. Zelenetz, A. D., Radioimmunotherapy for lymphoma. Curr. Opin. Oncol. 1999, 11, 375-380.
15. Press, O. W., Rasey, J., Principles of radioimmunotherapy for hematologists and oncologists. Semin. Oncol. 2000, 27 (6 Suppl 12), 62-73.
16. Press, O. W., Rasey, J., Principles of radioimmunotherapy for hematologists and oncologists. Semin. Oncol. 2000, 27 (6 Suppl 12), 62-73.
17. Fuks, Z., H. S. Kaplan, Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas. Radiology 1973, 108, 675-684.
18. Parker, D., D. L. Alison, Barnard, D. L., Child, J. A. et al., Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level. Hematol. Oncol. 1994, 12, 15-27.
19. White, C. A., Halpern, S. E., Parker, B. A., Miller, R. A. et al., Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 1996, 87, 3640-3649.
20. Bischof Delaloye, A., The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL). Leuk. Lymphoma 2003, 44 Suppl 4, S29-36.
21. 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr. Pharm. Biotechnol. 2001, 2, 341-349.
22. Knox, S. J., Goris, M. L., Trisler, K., Negrin, R. et al., Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 1996, 2, 457-470.
23. 90Y-labeled anti-CD20 monoclonal antibody. Clin. Cancer Res. 1999, 5(10 Suppl), 3281s-3286s.
24. Vriesendorp, H. M., Herpst, J. M., Germack, M. A., Klein, J. L. et al., Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J. Clin. Oncol. 1991, 9, 918-928.
25. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C. et al., Treatment with ibritumomab tiuxetan radioimmunetherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 2002, 20, 3262-3269.
26. Griesinger, F, Truemper, L., Myeloablative Hochdosis RIT bei rezidivierten B-Zell NHL mit 131I Rituximab: Erfahrungen der Göttinger RIT Gruuppe, in: Truemper, L. (Ed.), Radioimmuntherapie in der Hämatologie und Onkologie, 1st edn. Uni-Med Science, Bremen 2007.
27. Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E. et al., Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A Phase II multicenter trial. Blood 2002, 99, 4336-4342.
28. Witzig, T. E., Gordon, L. I., Cabanillas, F., Guczman, M. S. et al., Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2002, 20, 2453-2463.
29. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Semin. Oncol. 2003, 30 (6 Suppl 17) 11-16.
30. Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I. et al., Phase I/II trial of IDEC-Y2B8 redioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 1999, 17, 3793-3803.
31. Wiseman, G. A., Leigh, B. R. et al., Tumor dosimetry results for Zevalin radioimmunotherapy (Abstracts of the American Society Hematology). Blood 2001, 98,
32. Morschhauser, F, Illidge, T., Huglo, D., Martinelli, G. et al., Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007, 110, 54-58.
33. Ansell, S. M., Ristow, K. M., Habermann, T. M., Wiseman, G. A. et al., Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J. Clin. Oncol. 2002, 20, 3885-3890.
34. 90Y-rediolabelled ibritumomab tiuxetan. Eur. J. Nucl. Med. Mol. Imaging 2007, (epub ahead of press 10.1007/ s00259-007-0372-y).
35. Dreyling, M., Trümper, L., v Schilling, C., Holtkmap, U. et al., Results of a national consensus workshop: Therapeutic algorithm in patients with follicular lymphoma - Role of radioimmunotherapy. Ann. Hemat. 2007, 86, 81-87.
36. 90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL) (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2006, 106.
37. Pervan, M., Calimlim, J., Matso, D., Said, J. V. et al., Active combination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo diffuse large B-cell lymphoma model (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2005, 106.
38. 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL) (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2005, 106.
39. Hamlin, P. A., Moskowitz, C. H. et al., Early safety and efficacy analysis of a Phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin®) for elderly high risk patients with untreated DLBCL (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2005, 106.
40. 90Y) ibritumomab tiuxetan (Zevalin) for previously untreated follicular lymphoma (FL) patients (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2005, 106.
41. Jurczak, W., Giza, A. et al., Consolidation of chemotherapy response in mantle cell lymphoma (MCL) patients with 90Y-ibritumomab tiuxetan (90Y-Zevalin) radioimmunotherapy (RIT) (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2005, 106.
42. Devizzi, L., Seregni, E. et al., High-dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has minimal toxicity and full feasibility in an outpatient setting (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2005, 106.
43. 90Yttrium ibritumomab tiuxetan) treatment with PBSC support in refractory-resistant NHL patients: Preliminary results of a Phase I/II study (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2005, 106.
44. Shimoni, A., Zwas, T. et al., Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin's lymphoma (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2006, 106.
45. Nademanee, A., Forman, S., Molina, A., Fung, H. et al., A phase 1/ 2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005, 106, 2896-2902.
46. Krishnan, A., A. Raubitschek, Forman, J. S., Fung, H. et al., New transplant strategies utilizing radioimmunotherapy (RIT) based regimens to reduce relapse in high risk mantle cell lymphoma (MCL) (Abstracts of the American Society Hematology, Atlanta, GA). Blood 2005, 106.
47. +B-cell lymphoma: long-term follow-up of aphase 1/2 study. Blood 2004, 103, 4429-4431.
48. Witzig, T. E., White, C. A., Gordon, L. I, Wiseman, G. A. et al., Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J. Clin. Oncol. 2003, 21, 1263-1270.